Ezh-108- A Phase I, Open-Label Multi-Dose Two-Part Study To Characterize The Effects Of A Strong Cyp3a4 Inhibitor And A Strong Cyp3a4 Inducer On The Steady-State Pharmacokinetics Of Tazemetostat (Epz-6438) In Subjects With Advanced Malignancies
Posted Date: May 6, 2021
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to characterize the steady-state PK of oral Tazemetostat and its metabolite EPZ 6930 when administered as a single and twice daily dose in subjects with advanced malignancies while taken alone or in combination with either itraconazole or rifampin.
Criteria:
Histologically And/Or Cytologically Confirmed Advanced Metastatic Or Unresectable Solid Tumors Has Progressed After Treatment For Which There Are No Standard Therapies Available, Ecog 0-2, Adequate Organ Function As Defined By Protocol, Life Expectancy Of
Keywords:
Phase 1, Advanced Malignancies
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com